Testing new inhibitors for colon cancer treatment
Official title: Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer
Run by Institut Paoli-Calmettes · NCT05955196 · Data updated 2026-11-12
This study is testing new drugs that aim to help the immune system fight colon cancer by blocking certain cells that make it harder for the body to attack tumors.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 115 (estimated) |
| Sponsor | Institut Paoli-Calmettes Academic / other |
| Locations | 1 site (Marseille) |
| Status | Recruiting |
| Started | January 9, 2023 |
| Main results expected | January 9, 2025 |
| Study ends | January 9, 2027 |
| Registry record updated | October 9, 2024 |
| Trial ID | NCT05955196 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with metastatic or non-metastatic colon cancer, or those experiencing recurrence for whom surgery is proposed.
✕Probably not a fit
Patients who have undergone emergency colon cancer surgery or are unable to provide consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to develop novel CD47-SIRPα inhibitors using small molecules to counteract immune suppression caused by tumor-associated macrophages in colon cancer. By employing structure-based drug design, the researchers seek to create selective and potent inhibitors that can effectively target the tumor microenvironment with reduced toxicity compared to traditional antibody therapies. The study will utilize organoids derived from patient biopsies to accurately model the immune interactions within tumors, allowing for a thorough evaluation of the immunotherapy's effectiveness.
Why it matters
Potential benefit: If successful, this approach could enhance anti-tumor immunity and improve treatment outcomes for patients with colon cancer.
How similar studies have gone: While this approach is innovative, similar studies targeting the immune microenvironment have shown promise, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over 18 years old * Patient who has signed a consent to participate; * Patient with metastatic or non-metastatic colon cancer, or recurrence of colon cancer for whom excision surgery has been proposed; * Patient affiliated to a social security scheme, or beneficiary of such a scheme Exclusion Criteria: * Patient who had emergency colon cancer surgery * Person in an emergency situation or unable to express their consent. * Adult subject to a legal protection measure (adult under guardianship, curatorship or safeguard of justice), * Patient unable to submit to the medical follow-up of the trial for geographical, social or psychological reasons
Where it's running
-
Institut Paoli Calmettes
Marseille, France Recruiting
Study contacts
- Principal investigator: Cécile de CHAISEMARTIN, MD — Paoli Calmettes Institute
- Study coordinator: Dominique GENRE, MD
- Email: drci.up@ipc.unicancer.fr
- Phone: +33491223778
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sports-inspired Onco-Coaching for Young Adults in Cancer Remission
We’re testing a sports-style coaching program to support young adults 18–25 who are in cancer remission, to see how many start the coaching and attend the first two sessions.
-
Metabolic and Microenvironment Patterns in Metastatic Pancreatic Cancer
Researchers are testing how metabolism and surrounding cells in pancreatic cancer relate to treatment responses, using biopsies and blood samples from patients with metastatic disease.
-
Biomarkers and Targets for Lung Immunotherapy in NSCLC
This study tests blood and tumor biomarkers to see who among adults with non-small cell lung cancer might respond to immunotherapy.
-
Evaluating the role of radiology manipulators in cancer imaging interpretation
This study is testing if a new tool can help doctors read cancer imaging better and faster by checking their work before they make a final report.
-
Delayed kidney removal after a strong response to immunotherapy for metastatic kidney cancer
This trial will test whether removing the remaining kidney after a very good response to immunotherapy lets people with metastatic kidney cancer stop systemic treatment and keep the cancer under control.
-
Stopping venetoclax plus azacitidine after about 12 months in AML responders
This trial will test whether stopping venetoclax plus azacitidine after about 12 months keeps adults with AML who are in remission and MRD-negative disease-free and safe.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.